Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease
Brewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. 2008, 153-166. DOI: 10.1017/cbo9780511666971.010.Peer-Reviewed Original ResearchTypes of patientsWilson's diseaseMaintenance therapyInitial treatmentZinc maintenance therapyDouble-blind trialOpen-label studyNeurologic Wilson diseaseWeeks of treatmentDouble-blind designAnticopper drugNeurologic worseningTM armNeurologic deteriorationIntolerant patientsMost patientsNeurologic presentationNeurologic symptomsIll patientsSuch patientsUrine studiesBlind designBlind trialPatientsLabel study